Generic Name: selonsertib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: NAFLD/NASH Medications

Company: Gilead Sciences

Approval Status: Experimental

Generic Version Available: No

Experimental Code: GS-4997


General Info

Selonsertib is a small-molecule inhibitor of apoptosis signal-regulating kinase 1 (ASK1) in Phase 3 clinical trials. Gilead announced disappointing results from this study. 


Dosage

Dosing Info: N/A


Side Effects

N/A


Last Reviewed: February 21, 2019